Biotech sponsors are facing new pressures—and the effects are rippling through the clinical research landscape.
In a recent feature by Clinical Trials Arena, Aditya Kotta, Executive Director of Strategy at Novotech, shares insights on how the current funding environment is influencing trial execution in the United States. With early- and mid-stage biotechs under growing pressure to conserve capital, sponsors are reassessing development priorities—and rethinking how and where to run their trials.
Key insights from the article include:
- A notable decrease in trial initiations linked to declining venture investment.
- How biotech sponsors are consolidating programs to preserve runway.
- The increasing appeal of cost-efficient geographies like Asia-Pacific for trial execution.
- Novotech’s perspective on how global CRO partnerships can help sponsors adapt without compromising scientific integrity or speed.
Kotta explains that many sponsors are shifting their development strategies to stretch limited resources further, prioritizing trial sites, regions, and CRO partners that can deliver both operational excellence and regulatory alignment across markets.